The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

There were no serious adverse events or treatment-related mortalities. Evidence Rating Level: 2 (Good) Study Rundown: Transfusion-dependent β-thalassemia (TDT) is a condition that results in iron ...

Thomas J. Klima, the Chief Commercial and Operating Officer of bluebird bio, Inc. (NASDAQ:BLUE), recently sold shares of the company’s common stock. According to a recent SEC filing, Klima disposed of ...

In a recent transaction, Richard A. Colvin, the Chief Medical (TASE:PMCN) Officer of bluebird bio, Inc. (NASDAQ:BLUE), sold shares of the company's common stock. On February 3, 2025, Colvin sold 64 ...

Thirty patients have received the gene therapy within a clinical trial and early-access program, and the foundation also hopes to seek approval in the US.

Oxford, UK - 5 February 2025: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the ...

Telethon Foundation is seeking approval for a gene therapy to treat the rare disease Wiskott-Aldrich syndrome.

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

Gene therapy using modified blood stem cells helped five adults with severe hemophilia A reach therapeutic levels of clotting ...

VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy ...

Dr. Walker was most recently Chief Medical Officer of Harpoon Therapeutics through its acquisition by Merck in 2024 including leadership over its immune-oncology work. Prior to joining Harpoon ...